

NCT02687724 Raw comparison:

Summary:
CHIA has 31 criteria while your personal folder has 34 criteria
Total found criteria: 30/31
Total not Found: 1/31
Total Extra: 3
This trial is INVALID



╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╕
│ CHIA Criteria                                      │ Matching Personal Criteria                         │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╡
│ Patients = 18 years of age                         │ Patients ≥ 18 years of age                         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subjects must be able and willing to give written  │ Subjects must be able and willing to give written  │
│ informed consent and to comply with the            │ informed consent and to comply with the            │
│ requirements of this study protocol                │ requirements of this study protocol                │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Established diagnosis of UC and moderate-to-severe │ Established diagnosis of UC and moderate-to-severe │
│ disease activity defined as a Mayo score of 6-12   │ disease activity defined as a Mayo score of 6-12   │
│ with an endoscopic subscore =2                     │ with an endoscopic subscore ≥2                     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patients had an inadequate response to or had      │ Patients had an inadequate response to or had      │
│ failed to tolerate 1 or more of the following      │ failed to tolerate 1 or more of the following      │
│ conventional therapies oral 5-aminosalicylates     │ conventional therapies oral 5-aminosalicylates     │
│ oral corticosteroids azathioprine (AZA) and/or     │ oral corticosteroids azathioprine (AZA) and/or     │
│ 6-mercaptopurine (6MP) or corticosteroid dependent │ 6-mercaptopurine (6MP) or corticosteroid dependent │
│ (ie an inability to taper corticosteroids without  │ (ie an inability to taper corticosteroids without  │
│ recurrence of UC symptoms)                         │ recurrence of UC symptoms)                         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patients concurrently treated with oral            │ Patients concurrently treated with oral            │
│ 5-aminosalicylates or corticosteroids were to      │ 5-aminosalicylates or corticosteroids were to      │
│ receive a stable dose for at least 2 weeks before  │ receive a stable dose for at least 2 weeks before  │
│ baseline and patients receiving AZA and/or 6MP     │ baseline and patients receiving AZA and/or 6MP     │
│ were to receive a stable dose for at least 4 weeks │ were to receive a stable dose for at least 4 weeks │
│ before baseline Patients were required to maintain │ before baseline Patients were required to maintain │
│ stable doses of their concomitant UC medications   │ stable doses of their concomitant UC medications   │
│ during the study                                   │ during the study                                   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Female subjects of child bearing potential must be │ Female subjects of child bearing potential must be │
│ willing to ensure that they or their partner use   │ willing to ensure that they or their partner use   │
│ effective contraception during the study and for 6 │ effective contraception during the study and for 6 │
│ months thereafter OR                               │ months thereafter OR                               │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Surgical sterilized female patients with           │ Surgical sterilized female patients with           │
│ documentation of prior hysterectomy tubal ligation │ documentation of prior hysterectomy tubal ligation │
│ or complete bilateral oophorectomy OR              │ or complete bilateral oophorectomy OR              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Postmenopausal women with postmenopausal defined   │ Postmenopausal women with postmenopausal defined   │
│ as permanent cessation >1 year of previously       │ as permanent cessation \>1 year of previously      │
│ occurring menses                                   │ occurring menses                                   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Female subjects' serum pregnancy test performed at │ Female subjects' serum pregnancy test performed at │
│ the screening visit and urine pregnancy test       │ the screening visit and urine pregnancy test       │
│ performed at the baseline visit must be negative   │ performed at the baseline visit must be negative   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subjects have following investigations within 1    │ Subjects have following investigations within 1    │
│ month prior to enrolment                           │ month prior to enrolment                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Routine bloods including U&E FBC LFTs inflammatory │ Routine bloods including U\&E FBC LFTs             │
│ markers (CRP) and albumin will be measured         │ inflammatory markers (CRP) and albumin will be     │
│                                                    │ measured                                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Medical history concomitant medications            │ Medical history concomitant medications            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Intradermal reaction to Tuberculin (PPD skin test) │ Intradermal reaction to Tuberculin (PPD skin test) │
│ or Mycobacterium tuberculosis antigenspecific      │ or Mycobacterium tuberculosis antigenspecific      │
│ interferon-gamma release assay (IGRA)              │ interferon-gamma release assay (IGRA)              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ TB screening chest X-Ray unless performed in the   │ TB screening chest X-Ray unless performed in the   │
│ last 6 months                                      │ last 6 months                                      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Stool examination for enteric pathogens including  │ Stool examination for enteric pathogens including  │
│ Clostridium difficile                              │ Clostridium difficile                              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Informed consent                                   │ Informed consent                                   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Mayo score (including sigmoidoscopy unless         │ Mayo score (including sigmoidoscopy unless         │
│ performed in previous 3 months)                    │ performed in previous 3 months)                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patient's weight and height and abdominal          │ Patient's weight and height and abdominal          │
│ circumference                                      │ circumference                                      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Female subjects who are pregnant or breast-feeding │ Female subjects who are pregnant or breast-feeding │
│ or considering becoming pregnant during the study  │ or considering becoming pregnant during the study  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patients aged <18 years of age                     │ Patients aged \<18 years of age                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patients who cannot give informed consent          │ Patients who cannot give informed consent          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Pregnant patients or those who are breastfeeding   │ Pregnant patients or those who are breastfeeding   │
│ will be deemed ineligible                          │ will be deemed ineligible                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Prior treatment with any anti-TNF agent            │ Prior treatment with any anti-TNF agent            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Contra-indication to use of GLM (Hypersensitivity  │ Contra-indication to use of GLM (Hypersensitivity  │
│ to the active substance or to any of the           │ to the active substance or to any of the           │
│ excipients Active tuberculosis (TB) acute or       │ excipients Active tuberculosis (TB) acute or       │
│ chronic Hepatitis B infection or other severe      │ chronic Hepatitis B infection or other severe      │
│ infections such as sepsis and/or opportunistic     │ infections such as sepsis and/or opportunistic     │
│ infections including HIV infection Moderate or     │ infections including HIV infection Moderate or     │
│ severe heart failure (NYHA class III/IV)           │ severe heart failure (NYHA class III/IV)           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Have symptoms or signs suggestive of current       │ Have symptoms or signs suggestive of current       │
│ active or latent TB upon medical history physical  │ active or latent TB upon medical history physical  │
│ examination and/or chest radiograph or positive    │ examination and/or chest radiograph or positive    │
│ Mycobacterium tuberculosis antigen-specific        │ Mycobacterium tuberculosis antigen-specific        │
│ interferon-gamma release assay (IGRA)              │ interferon-gamma release assay (IGRA)              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patients with a history of or at imminent risk for │ Patients with a history of or at imminent risk for │
│ colectomy who required gastrointestinal surgery    │ colectomy who required gastrointestinal surgery    │
│ within 2 months before screening                   │ within 2 months before screening                   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of colonic mucosal dysplasia or            │ History of colonic mucosal dysplasia or            │
│ adenomatous colonic polyps that were not removed   │ adenomatous colonic polyps that were not removed   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Screening stool study positive for enteric         │ Screening stool study positive for enteric         │
│ pathogens or Clostridium difficile toxin           │ pathogens or Clostridium difficile toxin           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Oral corticosteroids at a dose >40 mg prednisone   │ Oral corticosteroids at a dose \>40 mg prednisone  │
│ or its equivalent per day receipt of cyclosporine  │ or its equivalent per day receipt of cyclosporine  │
│ tacrolimus sirolimus or mycophenolate mofetil      │ tacrolimus sirolimus or mycophenolate mofetil      │
│ within 8 weeks before the first study agent        │ within 8 weeks before the first study agent        │
│ injection or use of an investigational agent       │ injection or use of an investigational agent       │
│ within 5 half-lives of that agent before the first │ within 5 half-lives of that agent before the first │
│ study agent injection                              │ study agent injection                              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patients in recent receipt of live vaccinations    │ Patients in recent receipt of live vaccinations    │
│ within 4 weeks prior to enrolment                  │ within 4 weeks prior to enrolment                  │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╛



╒═══════════════════════════════════════╕
│ CHIA Criteria Not Found in Personal   │
╞═══════════════════════════════════════╡
│ Inclusion/exclusion criteria          │
╘═══════════════════════════════════════╛



╒═══════════════════════════════════╕
│ Extra Personal Criteria           │
╞═══════════════════════════════════╡
│ Inclusion/                        │
├───────────────────────────────────┤
│ Exclusion Criteria                │
├───────────────────────────────────┤
│ Must have minimum age of 18 Years │
╘═══════════════════════════════════╛